Articles Tagged With: oral
-
Iptacopan Capsules (Fabhalta)
The U.S. Food and Drug Administration has approved the first oral drug to treat paroxysmal nocturnal hemoglobinuria (PNH). Iptacopan is a first-in-class oral selective inhibitor of complement factor B (C3 pathway). It is distributed by Novartis Pharmaceutical Corporation as Fabhalta.
-
Oral vs. IV Iron for the Treatment of Iron-Deficiency Anemia in Pregnant Women
Compared to oral iron, intravenous iron reduced maternal anemia at delivery (40% vs. 85%, P = 0.039), and rates of maternal hemoglobin < 10 g/dL were lower with intravenous iron compared to oral iron (10% vs. 54%, P = 0.029). Rates of mild to moderate adverse events were similar between the two groups, and no severe adverse reactions were noted with intravenous iron.
-
Aetna Combines Data With Clinical Insight for Quality Improvement
A pair of data-driven quality improvement initiatives are helping Aetna improve care in two different areas. One involves improving oral hygiene to reduce infections; another helps reduce opioid-related deaths by contacting patients after an overdose.
-
Revamping the Daily Pill: Research to Begin on Monthly Pill
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
-
Oral Antibiotics Are Noninferior to Intravenous for Bone and Joint Infections
In a randomized, controlled trial of adult patients with bone or joint infections, researchers found oral antibiotic therapy was noninferior to intravenous therapy based on treatment failure at one year.
-
IV to Oral Conversion of Antibiotic Therapy for Bacteremia Due to Enterobacteriaceae
Oral step-down antibiotic therapy (IV to oral conversion) is safe and effective in patients with bloodstream infection due to Enterobacteriaceae.
-
Oral Linezolid for Staphylococcus aureus Bacteremia
Investigators evaluated 135 patients with Staphylococcus aureus bacteremia (SAB) in a prospective cohort study comparing early switch to oral linezolid to continued treatment with standard parenteral therapy (SPT). Patients with complicated SAB and osteoarticular infection were excluded. Early switch to oral therapy yielded similar outcomes to continued SPT and allowed earlier hospital discharge.
-
HIV Testing: Time to Combat Missed Opportunities
Results of a recent national analysis suggest that many people who are infected with HIV but not aware of their infection were not offered HIV testing during recent clinical visits.
-
Deaths From Ovarian Cancer Fall Worldwide Due to Oral Contraceptive Use, Data Show
Deaths from ovarian cancer fell worldwide between 2002 and 2012 and are predicted to continue to decline through 2020 in the United States, European Union, and, to a lesser extent, in Japan, according to newly published research. The primary reason is the use of oral contraceptives and the long-term protection against ovarian cancer that they provide, say researchers.
-
Where do pills fit in the family planning picture?
In national statistics, the pill continues to lead the pack, with 25.9% of contracepting women (9.7 million women) reporting its use. Female sterilization was listed by 25.1% (9.4 million women), followed by the male condom (15.3%, 5.8 million women) and long-acting reversible contraception (11.6%, 4.4 million women).